Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment

Authors:

Abstract
SUMMARY: BACKGROUND: We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children. METHODS: Perform was a randomised, open-label, cross-over trial of the relative bioavailability of LVX dispersible vs. crushed non-dispersible tablets in children aged n = 14, 56%), vomiting/spitting out medicines ( n = 11, 44%), and children refusing medicines ( n = 10, 40%). Caregivers reported that the dispersible formulation was easier for their child to take than the non-dispersible formulation ( P = 0.0253). Mean ranks for caregiver’s formulation preferences (dispersible tablets: 1.48, SD ±0.71; non-dispersible tablets: 2.12, SD ±0.67; routinely available formulations: 2.40 SD ±0.82) differed significantly (Friedman’s F 11.120; P < 0.0038); post-hoc testing showed dispersible tablets were preferred over non-dispersible ( P = 0.018) and routinely available LVX formulations ( P < 0.001). CONCLUSIONS: The dispersible LVX 100 mg tablet formulation was preferred and should be prioritised for integration into routine care.

This publication has 35 references indexed in Scilit: